NASDAQ · CNSP
Healthcare · Biotechnology
$5.35
Up+$0.00 (+0.00%)
Updated Oct 10, 2026, 9:05 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CNSP
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
CNSP closed at $5.35 after 21 trading sessions, down 8.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $5.35 | $5.35 | $5.34 | $5.35 | 1.16K |
| Oct 8, 2026 | $5.3601 | $5.3601 | $5.35 | $5.35 | 1.78K |
| Oct 7, 2026 | $5.35 | $5.44 | $5.0821 | $5.43 | 2.7K |
| Oct 6, 2026 | $5.40 | $5.45 | $5.3018 | $5.3018 | 6.21K |
| Oct 5, 2026 | $5.50 | $5.50 | $5.30 | $5.30 | 2.35K |
| Oct 2, 2026 | $5.23 | $5.40 | $5.11 | $5.3248 | 10.9K |
| Oct 1, 2026 | $5.35 | $5.35 | $5.2403 | $5.2403 | 878.28 |
| Sep 30, 2026 | $5.25 | $5.475 | $4.9301 | $5.30 | 8.02K |
| Sep 29, 2026 | $4.9073 | $4.9073 | $4.9073 | $4.9073 | 547.67 |
| Sep 28, 2026 | $4.982 | $5.11 | $4.9701 | $5.11 | 2.36K |
| Sep 25, 2026 | $5.21 | $5.21 | $4.931 | $4.931 | 1.27K |
| Sep 24, 2026 | $5.15 | $5.15 | $5.15 | $5.15 | 1.93K |
| Sep 23, 2026 | $5.15 | $5.15 | $5.15 | $5.15 | 2.94K |
| Sep 22, 2026 | $5.245 | $5.245 | $5.00 | $5.2392 | 2.68K |
| Sep 21, 2026 | $5.12 | $5.50 | $5.12 | $5.2186 | 2.34K |
| Sep 18, 2026 | $5.12 | $5.12 | $5.06 | $5.11 | 4.39K |
| Sep 17, 2026 | $5.35 | $5.35 | $5.05 | $5.12 | 2.66K |
| Sep 16, 2026 | $5.54 | $5.54 | $5.50 | $5.50 | 3.9K |
| Sep 15, 2026 | $5.70 | $5.70 | $5.70 | $5.70 | 2.02K |
| Sep 14, 2026 | $5.70 | $5.70 | $5.70 | $5.70 | 1.04K |
| Sep 11, 2026 | $5.845 | $5.845 | $5.73 | $5.84 | 18.54K |
The latest Smart Investors Daily articles mentioning CNSP.
Company
Market Activity
Research & News
CNSP research
Company profile and research snapshot.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 12, 2025 | Maxim Group | Buy | — |
| Mar 25, 2025 | Maxim Group | Hold | — |
| Sep 10, 2024 | Maxim Group | Buy | — |
| Feb 2, 2021 | Brookline Capital | Buy | — |
| Aug 24, 2020 | Ladenburg Thalmann | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 30, 2026
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call September 30, 2026 12:00 PM EDTCompany ParticipantsRami Levin - President, CEO & DirectorSteve...
Yahoo · Sep 1, 2026
Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" SegmentAccess the segment hereHOUSTON, TX / ACCESS Newswire / September 1, 2026 / (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment.Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provided an update on
Yahoo · Aug 27, 2026
Video webcast now available hereHOUSTON, TX / ACCESS Newswire / August 27, 2026 / (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference.Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's strategic transformation that is being built on the strength of
Yahoo · Aug 12, 2026
Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CNSP.
